An interventional study of Sham RIC and Remote Ischemic Conditioning treatment instrument in Subarachnoid Hemorrhage, Cerebrovascular Disorders and Brain Diseases, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment
Several recent large-scale clinical trials aimed at improving subarachnoid hemorrhage(SAH) outcomes have concluded with negative results, failing to enhance the prognosis for these patients. Consequently, there is an urgent demand for novel treatment strategies and approaches to address the challenges posed by SAH.
Remote ischemic conditioning(RIC) has gained considerable attention in the treatment of stroke, particularly ischemic stroke, with numerous studies demonstrating its potential to enhance neurological outcomes compared to conventional treatments alone.RIC for the treatment of SAH is an investigative strategy in its initial stages. The neuroprotective effects of RIC, particularly its potential to preserve cranial nerve function and ameliorate neurological deficits, confer significant value in the treatment of SAH patients.
The precise manner in which SAH patients may benefit from RIC treatment, and the mechanisms by which it improves neurological function, remain to be fully understood. Consequently, randomized controlled trials are necessary to validate the efficacy of RIC in this patient population and to delineate the optimal therapeutic protocols for its application.
Based on the above discussion, this study aims to explore the efficacy and safety of RIC in the treatment of SAH.
509 studies on the registry are indexed under Subarachnoid Hemorrhage; 124 are open to participants now.
This study's planned enrollment of 500 is above the median of 52 across 263 interventional studies indexed under Subarachnoid Hemorrhage.
Browse Subarachnoid Hemorrhage studies →Beijing Tiantan Hospital is the lead sponsor of 465 studies on the registry; 282 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Guideline-based therapy+Sham RIC is given twice a day with 60mmHg pressure.
Device: Sham RIC
Guideline-based therapy+RIC RIC is given twice a day with 200mmHg pressure.
Device: Remote Ischemic Conditioning treatment instrument
Remote Ischemic Conditioning is given twice a day with 60mmHg pressure.
Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
Proportion of mRS (0-2)
Modified Rankin Scale, mRS; min:0, max:6; A smaller score indicates a better prognosis.
Time frame: 90±7 days
Proportion of mRS (0-1)
Modified Rankin Scale, mRS; min:0, max:6; A smaller score indicates a better prognosis.
Time frame: 90±7 days
mRS Score as ordinal variable
Modified Rankin Scale, mRS; min:0, max:6; A smaller score indicates a better prognosis.
Time frame: 7±1 days
mRS Score as ordinal variable
Modified Rankin Scale, mRS; min:0, max:6; A smaller score indicates a better prognosis.
Time frame: 30±7 days
Cognitive function score as ordinal variable
Montreal Cognitive Assessment, MoCA. The total score is 30, with higher scores indicating better cognitive function.
Time frame: 7±1 days
The complete blood count
up to 30 days
Time frame: During hospitalization
Plan to share: Yes — De-identified participant data and study materials will be accessible.
Supporting information: Study protocol, Sap, Icf, Csr
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Tiantan Hospital